In this Healio Video Perspective from the Macula Society meeting, Dilsher Dhoot, MD, discusses data from three phase 3 trials involving pegcetacoplan and avacincaptad pegol for the treatment of geographic atrophy.
The analysis looked at findings from the phase 3 OAKS and DERBY trials, which included eyes with both nonsubfoveal and subfoveal geographic atrophy (GA) lesions and monthly and every other month dosing of pegcetacoplan, and the GATHER2 trial, which included eyes with nonsubfoveal GA lesions and initial monthly and later monthly and every other month dosing of avacincaptad pegol